AKTX Stock Summary and Trading Ideas (Akari Therapeutics PLC - American Depositary Shares | NASDAQ:AKTX)

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Akari Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AKTX.

As of December 29, 2025, AKTX stock price declined to $0.26 with 685,937 million shares trading.

AKTX has a beta of 0.70, meaning it tends to be less sensitive to market movements. AKTX has a correlation of 0.02 to the broad based SPY ETF.

AKTX has a market cap of $9.35 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, AKTX traded as high as $11.00 and as low as $.22.

AKTX has underperformed the market in the last year with a price return of -73.0% while the SPY ETF gained +16.8%. AKTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -74.4% and -36.4%, respectively, while the SPY returned +3.9% and +1.3%, respectively.

AKTX support price is $.24 and resistance is $.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTX shares will trade within this expected range on the day.